Clinical Trials Sponsored by Tigris Pharmaceuticals

Total 19608 results

Tigris Pharmaceuticals

Withdrawn

Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

Breast Neoplasm
Tigris Pharmaceuticals

Completed

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) (TG-003)

Cervical Intraepithelial Neoplasia | Uterine Cervical Dysplasia

United States
Tigris Pharmaceuticals

Terminated

Study of AFP464 +/- Faslodex in ER + Breast Cancer

Breast Neoplasm

United States
Tigris Pharmaceuticals

Completed

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

Cervical Intraepithelial Neoplasia | Uterine Cervical Dysplasia

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Solid Tumor

Germany
Tigers Running Club

Active, not recruiting

Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals (WIM_22)

Breast Cancer | Cancer Survivors | Exercise Oncology | Fitness Capacity

Spain
Tigran Technologies AB

Completed

Reconstruction of Peri-implant Osseous Defects: A Randomized Trial

Peri-implantitis

Sweden
Mekelle University
Tigray Development Association; Mums for Mums; Tigray Health Research Institute; Tigray Health Bureau and other collaborators

Recruiting

Effectiveness of Local Food Solutions for the Prevention of Acute Malnutrition in Tigray, Northern Ethiopia (ELOFSAM) (ELOFSAM)

Acute Malnutrition in Childhood

Ethiopia
Sigrid Therapeutics AB

Recruiting

Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21® (SHINE)

Overweight or Obesity

Slovakia, Poland, Romania
Pieris Australia Pty Ltd

Completed

Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

Healthy

Australia
Pieris Australia Pty Ltd

Completed

Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Healthy Subjects

Australia
Sigrid Therapeutics AB

Completed

STAR Study Investigating Performance and Safety of the Medical Device SiPore15™

Overweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre Diabetes

Finland, Sweden
Taris Biomedical LLC

Completed

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

United States, Netherlands
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

Netherlands
Pieris Australia Pty Ltd

Completed

Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Asthma

Australia
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Samia Girgis

Unknown

Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)

Coronavirus Disease 2019 (COVID19)

Egypt
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Idiopathic Overactive Bladder With Urinary Incontinence

United States
Allergan
TARIS Biomedical, Inc.

Terminated

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Interstitial Cystitis

United States, Canada
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Neurogenic Detrusor Overactivity

United States
TARIS Biomedical, Inc.

Completed

Safety and Tolerability Study of the Taris Placebo System

Healthy

United States
University of California, Davis
CITRIS

Terminated

Feasibility of a Non-invasive, Trans-abdominal, Low Cost Fetal Oximetry Probe on Pregnant Human Subjects

Pregnancy, Abdominal

United States
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine

Clinical Trials Sponsored by Tigris Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations